I. Kaweewan et al.
report [26]. The peptides were tested against bacterial strains
including E. coli, P. aeruginosa, S. aureus, B. subtilis, and M.
luteus. Tetracycline was used as a positive control. Using the
broth dilution technique with Mueller-Hinton Broth (MHB),
serial twofold dilution of the compounds (1 and 5) and
tetracycline were prepared (50 µl/well), ranging from 64 to
12. Curtis RW. Root curvatures induced by culture filtrates of
Aspergillus niger. Science. 1958;128:661–2.
1
3. Wang J, et al. Study of malformin C, a fungal source cyclic
pentapeptide, as an anti-cancer drug. PLoS One. 2015;10:
e0140069.
14. Liu Y, et al. Malformin A1 promotes cell death through induction
of apoptosis, necrosis and autophagy in prostate cancer cells.
Cancer Chemother Pharm. 2016;77:63–75.
−1
0
.0625 µg ml . Test bacteria were diluted with MHB to give
1
1
1
5. Koizumi Y, Nagai K, Hasumi K, Kuba K, Sugiyama T.
Structure–activity relationship of cyclic pentapeptide malformins as
fibrinolysis enhancers. Bioorg Med Chem Lett. 2016;26:5267–71.
6. Ma Y-M, Liang X-A, Zhang H-C, Liu R. Cytotoxic and antibiotic
cyclic pentapeptide from an endophytic Aspergillus tamarii of
Ficus carica. J Agric Food Chem. 2016;64:3789–93.
7. Nakamura F, et al. Kakeromamide A, a new cyclic pentapeptide
inducing astrocyte differentiation isolated from the marine cya-
nobacterium Moorea bouillonii. Bioorg Med Chem Lett. 2018;
28:2206–9.
5
−1
a final inoculum of 10 CFU ml . The bacterial solution
50 µl) was transferred to each well, which contain a various
(
concentrations of testing compound. The MICs was deter-
mined as the lowest concentration that gave no visible growth
after incubation of the microplates at 30 °C for 24 h.
Acknowledgements This study was supported by the Japan Society
for the Promotion of Science by Grants-in-aids (grant number
1
6K01913). The NMR spectra were recorded on Bruker Avance 600
18. Kojiri K, et al. Endothelin-binding inhibitors, BE-18257A and
BE-18257B. I. Taxonomy, fermentation, isolation and character-
ization. J Antibiot. 1991;44:1342–7.
and Avance III HD 800 spectrometers at Advanced Analysis
Center, NARO.
1
2
2
9. Nakajima S, Niiyama K, Ihara M, Kojiri K, Suda H. Endothelin-
binding inhibitors, BE-18257A and BE-18257B II. Structure
determination. J Antibiot. 1991;44:1348–56.
0. Jang J-P, et al. Pentaminomycins A and B, hydroxyarginine-
containing cyclic pentapeptides from Streptomyces sp. RK88-
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
1
441. J Nat Prod. 2018;81:806–10.
1. Labeda DP. Taxonomic evaluation of putative Streptomyces sca-
biei strains held in the ARS Culture Collection (NRRL) using
multi-locus sequence analysis. Antonie Van Leeuwenhoek. 2016;
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
1
09:349–56.
2
2. Shirling EB, Gottlieb D. Methods for characterizing Streptomyces
species. Int J Syst Bacteriol. 1966;16:313–40.
References
2
3. Harada K, Fujii K, Hayashi K, Suzuki M, Ikai Y, Oka H.
Application of D,L-FDLA derivatization to determination of
absolute configuration of constituent amino acids in peptide by
advanced Marfey's method. Tetrahedron Lett. 1996;37:3001–4.
4. Inglis AS, Nicholls PW, Roxburgh CM. Hydrolysis of the peptide
bond and amino acid modification with hydriodic acid. Aust J Biol
Sci. 1971;24:1235–40.
5. Muramoto K, Kamiya H. Recovery of tryptophan in peptides and
proteins by high-temperature and short-term acid hydrolysis in the
presence of phenol. Anal Biochem. 1990;189:223–30.
6. Di Modugno E, Erbetti I, Ferrari L, Galassi G, Hammond SM,
Xerri L. In vitro activity of the tribactam GV104326 against
Gram-positive, Gram-negative, and anaerobic bacteria. Anti-
microb Agents Chemother. 1994;38:2362–8.
7. Prieto C, Garcia-Estrada C, Lorenzana D, Martin JF. NRPSsp:
non-ribosomal peptide synthase substrate predictor. Bioinfor-
matics. 2012;28:426–7.
1
2
3
4
. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents
Chemother. 1999;43:1317–23.
. Levine DP. Vancomycin: a history. Clin Infect Dis 2006;42 Suppl
1
:S5–12.
2
2
2
. Hubbard BK, Walsh CT. Vancomycin assembly: nature's way.
Angew Chem Int Ed. 2003;42:730–65.
. Dinos GP, et al. Chloramphenicol derivatives as antibacterial and
anticancer agents: historic problems and current solutions. Anti-
biotics. 2016;5:E20.
5
6
7
8
9
. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a
lipopeptide antibiotic for the treatment of serious gram-positive
infections. J Antimicrob Chemother. 2005;55:283–8.
. Henson KE, Levine MT, Wong EA, Levine DP. Glycopeptide
antibiotics: evolving resistance, pharmacology and adverse event
profile. Expert Rev Anti Infect Ther. 2015;13:1265–78.
. Marks TA, Venditti JM. Potentiation of actinomycin D or
adriamycin antitumor activity with DNA. Cancer Res. 1976;36:
2
2
2
8. Blin K, et al. antiSMASH 5.0: updates to the secondary metabolite
genome mining pipeline. Nucleic Acids Res. 2019;47:W81–7.
9. Kuranaga T, et al. Total synthesis of the nonribosomal peptide
surugamide B and Identification of a new offloading cyclase
family. Angew Chem Int Ed Engl. 2018;57:9447–51.
4
96–504.
. Dorr RT, Meyers R, Snead K, Liddil JD. Analytical and biological
inequivalence of two commercial formulations of the antitumor
agent bleomycin. Cancer Chemother Pharm. 1998;42:149–54.
. Tedesco D, Haragsim L. Cyclosporine: a review. J Transpl.
3
0. Matsuda K, et al. SurE is a trans-acting thioesterase cyclizing two
distinct non-ribosomal peptides. Org Biomol Chem. 2019;17:
2
012;2012:230386.
1
0. Süssmuth RD, Mainz A. Nonribosomal peptide synthesis - prin-
ciples and prospects. Angew Chem Int Ed. 2017;56:3770–821.
1. Curtis RW. Curvatures and malformations in bean plants caused by
culture filtrate of Aspergillus niger. Plant Physiol. 1958;33:17–22.
1
058–61.
3
1. Kodani S, et al. Sphaericin, a lasso peptide from the rare actino-
1
mycete Planomonospora sphaerica. Eur J Org Chem. 2017;2017:
1
177–83.